Phase I/II Study of SCTB39-1 in Advanced Solid Tumours

Summary

This study aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB39-1 as a monotherapy in adult patients with advanced malignant solid tumours. This study is an open label, multicentre, dose-escalation and dose-expansion Phase I/II clinical trial.

Timeline

Start

2025-06-23

Primary completion

2028-06-30

Completion

2028-06-30

Drugs

Indications